Atlas Trials

Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

Clinical trial NCT02386501 · COMPLETED

Trial details

NCT number
NCT02386501
Sponsor
Advaxis, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
HER2 Expressing Solid Tumors
Start date
2015-09-01
Primary completion
2017-04-01
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.